Summary

Women's health is one of the biggest missed opportunities in global healthcare — and in the global economy. Despite making up half the world's population, women have been systematically underserved by research, funding, and care delivery. This white paper breaks down why that matters economically, where the investment opportunities are, and what needs to change.

• Key numbers:

  • Closing the women's health gap could add $1 trillion+ to the global economy annually by 2040

  • Women spend an average of 9 more years in poor health than men, directly impacting workforce participation and productivity

  • Only 5% of global healthcare R&D funding goes toward women's health

  • The gap costs 75 million years of life lost to poor health or early death every year

  • Addressing it could unlock the equivalent of 137 million women entering full-time employment by 2040

Table of Contents

1. Introduction

2. The Economic Case for Women's Health Investment

2.1 Global Economic Impact

2.2 Workforce Participation and Productivity

2.3 Multigenerational Benefits

3. The Women's Health Gap: A Global Perspective

3.1 Defining the Health Gap

3.2 Regional Disparities

3.3 Key Health Conditions Affecting Women

4. United States vs. Global Comparison

4.1 Healthcare Spending and Outcomes

4.2 Research and Development Investment

4.3 Access and Affordability Challenges

5. Root Causes of the Women's Health Gap

5.1 Scientific and Research Gaps

5.2 Data Collection and Analysis Deficiencies

5.3 Care Delivery System Failures

6. Economic Sectors and Investment Opportunities

6.1 Reproductive Health

6.2 Menopause and Aging

6.3 Cardiovascular and Chronic Diseases

6.4 Mental Health and Nutrition

7. Recommendations

7.1 For Policymakers

7.2 For Healthcare Providers

7.3 For Investors and Private Sector

7.4 For Research Institutions

8. Conclusion

9. References

1. Introduction

For most of modern medicine's history, women's health has been treated as a footnote — or reduced to reproductive health entirely. The reality is far broader. Cardiovascular disease, autoimmune disorders, mental health, chronic pain, nutrition — across nearly every category, women face worse outcomes, later diagnoses, and less effective treatments.

The cost of this isn't just human. It's economic. Women globally spend 25% more time in poor health than men — roughly 9 years of reduced quality of life. That translates directly into lost workforce participation, lower productivity, strained families, and slower economic growth. The effects ripple outward across communities and generations.

The McKinsey Health Institute puts a number on it: closing the women's health gap could inject at least $1 trillion annually into the global economy by 2040. And that's likely a conservative estimate, given how much we still don't measure.

This white paper looks at the economic case for investing in women's health — from both a global and US perspective. We dig into the root causes of the gap, identify where the real investment opportunities are, and lay out concrete recommendations for policymakers, providers, investors, and researchers.

Because this isn't just the right thing to do. It's the smart thing to do.

2. The Economic Case for Women's Health Investment

2.1 Global Economic Impact

The economic case isn't subtle. McKinsey estimates that closing the women's health gap represents a $1 trillion annual opportunity by 2040 — driven by four pathways:

• Fewer early deaths among working-age women

• Fewer health conditions reducing quality of life

• Longer economic participation — women staying in the workforce longer

• Higher productivity — less absenteeism, better performance

Right now, the gap costs 75 million disability-adjusted life years (DALYs) annually — roughly seven days per woman per year lost to poor health or premature death. Closing it would be the equivalent of 137 million women entering full-time work by 2040.

And the returns compound. The African Development Bank found that for every $10 earned by women entrepreneurs in Africa, $9 goes back into families and communities. Investing in women's health doesn't just help women — it multiplies across entire economies.

2.2 Workforce Participation and Productivity

Nearly half of the women's health burden hits during peak working years (ages 15–50). The economic fallout is real:

• Healthcare costs: In the US, working women spend 18% more on healthcare than men — often for less effective care. That forces trade-offs no one should have to make.

• Absenteeism: In Bangladesh, 73% of women in textile factories missed an average of six days per month due to menstrual health issues. When they were given menstrual products and education, absenteeism dropped to 3%. The fix was simple. The impact was massive.

• Career disruption: Unmanaged reproductive health conditions — and lack of access to family planning — lead to unintended career setbacks, job loss, and reduced earning potential.

• Productivity loss: Conditions like endometriosis affect roughly 10% of women of reproductive age and can cause debilitating pain that goes undiagnosed for an average of 10 years. Women are working through it — but at what cost?

2.3 Multigenerational Benefits

This isn't just about the current generation. Investing in women's health creates a cascade of positive outcomes:

• Maternal and child health: Healthy mothers have healthier children. Pregnancy complications don't just end at delivery — gestational hypertension leads to chronic hypertension, and women with gestational diabetes face a 50% chance of developing type 2 diabetes within 7–10 years.

• Education: When mothers are healthy, their children perform better in school. It's that direct.

• Economic mobility: Healthy women can pursue education and careers. One Kenyan entrepreneur credited access to contraceptives with enabling her to build a business and send her daughter to study biomedical engineering.

• Community development: In Africa, where one in four women is involved in entrepreneurship, women's health isn't a personal issue — it's an economic engine.

3. The Women's Health Gap: A Global Perspective

3.1 Defining the Health Gap

The women's health gap isn't just about biology. It's about structural failures — in research, funding, and care delivery — that leave women spending 25% more time in poor health than men. That's roughly 9 extra years over a lifetime.

And here's the part most people get wrong: reproductive health accounts for only about 5% of the women's health burden. The other 95% breaks down like this:

• 56% comes from conditions that are more prevalent in women or show up differently — cardiovascular disease, autoimmune disorders, and others

• 39% comes from conditions that affect both sexes equally, but where women get worse care

So when someone says "women's health" and means "reproductive health," they're missing almost the entire picture.

3.2 Regional Disparities

The gap exists everywhere, but it's not evenly distributed.

• Maternal mortality: In 2020, roughly 800 women died every day from preventable pregnancy-related causes — one every two minutes. 94% of those deaths happened in low-resource settings, with 86% concentrated in sub-Saharan Africa and Southern Asia.

• Cervical cancer: Less than 25% of low-income countries have introduced the HPV vaccine, compared to 85% of high-income countries. Only 36% of women worldwide have ever been screened — and in LMICs, that drops below 20%.

• Malnutrition: It disproportionately hits women and girls, costing the global economy over $1.6 trillion annually. In many regions, cultural norms still prioritize feeding men first.

• Access to care: In rural areas of developing countries, the barriers stack up — distance, cost, cultural restrictions on mobility, and limited decision-making power over their own health.

3.3 Key Health Conditions Affecting Women

Several conditions either hit women harder or get missed entirely because medicine was built around male bodies:

• Cardiovascular disease: The leading killer globally for both sexes — but women are twice as likely to die from a serious heart attack. Their symptoms present differently, get misdiagnosed more often, and treatments can be 20% less effective.

• Endometriosis: Affects an estimated 10% of women of reproductive age — potentially 190 million women worldwide. Average time to diagnosis? 10 years. Research funding has been minimal despite the severity.

• Menopause: Affects most women, yet symptoms are rarely even counted in disease burden classifications. Mood swings and depression get misdiagnosed as standalone conditions instead of being connected to the hormonal picture.

• Autoimmune disorders: Approximately 80% of autoimmune patients are women, yet research has historically been built on male subjects.

• Mental health: Women experience depression and anxiety at higher rates — driven by hormonal changes, societal pressures, and the invisible weight of unpaid care work.

4. United States vs. Global Comparison

4.1 Healthcare Spending and Outcomes

The United States presents a paradox: we spend more on healthcare than any other nation, yet American women face some of the worst disparities in the developed world.

• Higher Costs, Worse Outcomes: Working women in the US spend 18% more on healthcare than men. That’s an average of $135 more in out-of-pocket expenses every year—much of it driven by higher copays for conditions that predominantly affect women.

• The Maternal Mortality Crisis: The US has the highest maternal mortality rate among developed nations. The numbers are even more staggering for women of color: Black and Native American women are 3 to 4 times more likely to die from pregnancy-related causes than White women, a gap that persists regardless of income.

• Global Comparison: Despite spending roughly 17% of our GDP on healthcare, the US lags behind other high-income countries in maternal mortality, life expectancy, and chronic disease management for women.

4.2 Research and Development Investment

The funding gap is just as stark. Whether in the US or abroad, women’s health is consistently underfunded.

In the United States:

• The NIH allocates only 11% of its budget to women’s health-specific research.

• Only 4.5% of funding for coronary artery disease supports women-focused research—even though women have a 50% higher mortality rate in the year following a heart attack.

• As of 2015, there were five times more studies on erectile dysfunction than on premenstrual syndrome.

Globally:

• Women’s health receives only 5% of global healthcare R&D funding.

• In the UK and Canada, only 5.9% of grants between 2009 and 2020 went to research examining female-specific outcomes.

• The Pipeline Problem: There is a tenfold higher volume of new therapies in development for women’s cancers compared to debilitating gynecological conditions like endometriosis.

4.3 Access and Affordability Challenges

Access barriers look different depending on where you are, but the themes are the same:

In the United States:

• Healthcare Deserts: Rural areas often lack specialists, forcing women to travel long distances for basic care.

• Coverage Gaps: Essential services, particularly fertility treatments, are often left out of standard insurance plans.

• Cost Barriers: High deductibles and copays prevent many women from seeking preventive care until a condition becomes an emergency.

Globally:

• Family Planning: 257 million women in developing regions who want to avoid pregnancy lack access to safe methods.

• Menstrual Equity: 500 million people worldwide lack access to basic menstrual products and hygiene facilities.

• Cultural Barriers: In many countries, women still need a male relative’s permission to access healthcare, and the stigma around reproductive health prevents millions from seeking help.

5. Root Causes of the Women's Health Gap

5.1 Scientific and Research Gaps

For decades, medical research has operated with a "male-default" mindset. Most biological studies and animal models have used male specimens, assuming the results would apply equally to women. They don’t.

• Treatment Effectiveness: In a study of 183 common medical interventions, 64% were found to be less effective or less accessible for women.

• Safety Risks: Since 2000, women in the US have reported adverse drug reactions 52% more frequently than men. Since 1980, medications have been 3.5 times more likely to be pulled from the market specifically because of safety risks to women.

• The Reality of Disparities: Asthma inhalers are roughly 20% less effective at reducing flare-ups in women. Even when cardiac procedures are technically successful, the age-adjusted risk of death or a major cardiac event is 20% higher for women.

This research gap alone accounts for roughly 60% of the total women's health gap.

5.2 Data Collection and Analysis Deficiencies

We can’t fix what we don’t measure. Data gaps exist at every stage of the healthcare journey:

• Inconsistent Definitions: There is no global standard for measuring things like menopause symptoms or chronic pelvic pain. If we can't define it consistently, we can't study it effectively.

• Missing Disaggregated Data: Only 25% of US clinical trials provide sex-disaggregated data. During the COVID-19 pandemic, only half of the world's countries reported cases by sex, and only 14% reported hospitalizations that way.

• Diagnostic Delays: A Danish study found that women are diagnosed later than men for more than 700 different diseases. For cancer, women wait an average of 2.5 years longer; for diabetes, it’s 4.5 years. Endometriosis? An average of 10 years to get a formal diagnosis.

These data failures contribute to approximately 25 million lost years of healthy life every year.

5.3 Care Delivery System Failures

Even when the science exists, the system often fails to deliver it:

• Awareness & Prevention: Many women aren't taught what "normal" symptoms look like, and healthcare providers often lack specific training on how diseases manifest differently in female patients.

• The "Pain Gap": Women’s pain is routinely underestimated and undertreated by clinicians.

• Misdiagnosis: Women are up to 7 times more likely to be misdiagnosed during a heart attack because diagnostic criteria are often based on male physiology.

• Cost & Access: In many countries, women face higher insurance premiums and out-of-pocket costs. Globally, 500 million people still lack access to basic menstrual products.

These systemic failures in how care is delivered account for 34% of the women's health gap.

6. Economic Sectors and Investment Opportunities

6.1 Reproductive Health

Reproductive health is more than a clinical need—it’s a massive market opportunity. From family planning to maternal health, the demand for innovation is global and growing.

• Market Activity: Private equity has poured over $80 billion into women’s health in the last four years alone. We’re seeing a median return of approximately 2.0x on invested capital over a 4–5 year horizon.

• Consolidation: Fertility clinics and IVF services are seeing significant consolidation as demand for family-building services scales.

• Innovation: It’s not just high-tech. Low-cost solutions like UNICEF’s uterine balloon tamponade (with a 95% success rate) and HPV vaccination programs (which can cut cervical cancer by 90%) offer massive returns on investment for global health.

6.2 Menopause and Aging

For a long time, menopause was the "silent" market. That’s changing. As more women remain in the workforce longer, the economic impact of untreated symptoms—from lost productivity to early retirement—is becoming impossible to ignore.

• The New Frontier: Major pharmaceutical players like Astellas and Bayer are developing non-hormonal treatments, and the FDA recently approved new drugs specifically for menopause management.

• Specialized Care: We’re seeing the rise of women-exclusive wellness centers and digital health platforms that focus entirely on the transition through menopause.

• Workplace Impact: Companies are starting to realize that supporting menopausal women isn't just a benefit—it’s a retention strategy for their most experienced talent.

6.3 Cardiovascular and Chronic Diseases

Cardiovascular disease is the leading cause of death for women, yet the "standard of care" was built for men. This is one of the most critical areas for new investment.

• The Opportunity: There is a massive need for sex-specific biomarkers for heart attack detection and gender-adapted protocols for cardiac care.

• Chronic Conditions: 80% of autoimmune patients are women, two-thirds of Alzheimer’s patients are women, and osteoporosis disproportionately affects post-menopausal women. These aren't niche markets—they are the majority.

• Proven Success: Standardized protocols work. In some systems, simple discharge checklists for heart failure reduced mortality by 65% for both sexes.

6.4 Mental Health and Nutrition

Mental health and nutrition are the foundations of economic empowerment. When women are healthy and nourished, they work more, earn more, and reinvest more.

• Mental Health: Women experience depression and anxiety at higher rates, often tied to hormonal shifts and the "invisible labor" of caregiving. There is a growing market for women-focused mental health services and digital therapeutics.

• Nutrition: Malnutrition costs the global economy over $1.6 trillion annually. Addressing this isn't just about food—it’s about supplements, education, and maternal health programs that create a multiplier effect for the next generation.

7. Recommendations

7.1 For Policymakers

• Mandate sex-disaggregated data in all health research and clinical trials. If we don't see the differences, we can't treat them.

• Incentivize women's health R&D through tax credits and economic benefits for companies focusing on underserved conditions.

• Increase public funding for women's health research to at least 20% of total health research budgets to match the actual disease burden.

• Require insurance coverage for essential services, including contraceptives, fertility treatments, and menopause care.

• Establish specialized health hubs, particularly in rural and underserved areas, to close the "healthcare desert" gap.

• Update medical school curricula to ensure the next generation of doctors understands how diseases manifest differently in women.

7.2 For Healthcare Providers

• Adopt gender-adapted clinical protocols for major conditions like cardiovascular disease and autoimmune disorders.

• Train staff on unconscious bias, specifically regarding how women’s pain is assessed and treated.

• Implement standardized screening to catch conditions like endometriosis and PCOS years earlier than the current average.

• Utilize telemedicine to reach women who face geographic or cultural barriers to in-person care.

• Track and report outcomes by sex to identify where your own system might be failing female patients.

7.3 For Investors and the Private Sector

• Look beyond reproductive health. Recognize that menopause, autoimmune disease, and cardiovascular care are massive, underserved markets.

• Provide growth-stage capital to help proven women's health startups scale globally.

• Support women entrepreneurs. Data shows they are more likely to repay loans and build sustainable businesses.

• Invest in AI and data tools that specifically target the gender data gap in diagnostics and drug development.

• Build workplace support programs for menstrual health and menopause to retain your most experienced talent.

7.4 For Research Institutions

• Ensure equal representation in clinical trials. Match enrollment to the actual disease burden in the population.

• Develop female-specific research tools, including animal and computational models that don't rely on a "male-default" biology.

• Study treatment efficacy differences. We need to know why certain drugs are less effective or more dangerous for women.

• Prioritize sex-specific biomarkers for earlier and more accurate diagnosis of heart attacks and chronic conditions.

• Increase funding for women investigators, which has been shown to lead to better enrollment of women in clinical trials.

8. Conclusion

The case for investing in women’s health is overwhelming. We are looking at a $1 trillion annual opportunity by 2040—a chance to improve the lives of billions of women while creating an economic ripple effect that spans generations.

Despite making up half the world’s population, women’s health still receives only 5% of global healthcare R&D funding. Women spend 25% more time in poor health than men, not because of biology alone, but because of systemic failures in how we research, collect data, and deliver care. These failures cost lives, drain productivity, and stall global growth.

The good news? The solutions are already here. From low-cost innovations like uterine balloon tamponades to AI-powered diagnostics and policy changes that mandate sex-disaggregated data, we have the tools to close the gap.

What we need now is action.

• Policymakers must prioritize women’s health in funding and regulation.

• Healthcare providers must update their clinical protocols to reflect sex and gender differences.

• Investors must recognize the massive market opportunity and provide the capital to scale these solutions.

• Researchers must ensure women are adequately represented and studied.

Investing in women isn’t charity; it’s sound economics. When women are healthy, they participate more fully in the workforce, earn more, and reinvest in their families and communities. The question isn’t whether we can afford to invest in women’s health—it’s whether we can afford not to.

9. References

McKinsey Health Institute. (2024). Closing the women's health gap: A $1 trillion opportunity to improve lives and economies.

Gates Foundation. (2023). The link between women's health and women's economic power.

World Economic Forum. (2025). Women's health is a $1 trillion opportunity that demands greater investment.

World Economic Forum. (2023). Healthcare equality in the United States: Addressing the gender gap.

American Progress. The economic, educational, and health-related costs of being a woman.

National Center for Biotechnology Information. (2020). Gender disparities in health and healthcare.

Nature. (2024). Women's health research funding gaps.

Deloitte. Health tech and women's health investment trends.

National Center for Biotechnology Information. (2024). Nutrition and women's health.

World Vision. (2023). Malnutrition disproportionately impacts women and girls, costs global economy over $1.6 trillion annually.

World Economic Forum. (2023). Malnutrition, poverty, and women: The inequality in pregnancy.

MDPI. (2024). Women's nutrition and health outcomes.

Psychiatry Online. Mental health as a critical factor in women's wellbeing.

American Psychological Association. Women and socioeconomic status.

National Women's Law Center. Reproductive health is part of the economic health of women and their families.

Science Direct. (2020). Reproductive health and economic outcomes.

RW Baird. (2025). Why menopause is the next big investment opportunity.

PharmaVoice. (2024). Menopause treatment developments.

CBS News. (2024). Menopause drug without hormones approved by FDA.

Institute for Women's Policy Research. (2025). Analysis: Costs of reproductive health restrictions.

Economic Policy Institute. The economics of abortion bans.

Population Reference Bureau. The sorry state of women's health in the United States.

UN Women. Everything you need to know about pushing for pay equity.

County Health Rankings. (2025). Gender pay gap data.

National Center for Biotechnology Information. (2018). Family duties and women's health.

National Center for Biotechnology Information. (2020). Work-family balance and women's health.

ETUI. Work and family: Double workload overburdens women's health.

Science Direct. (2021). Family responsibilities and health outcomes.

Gates Foundation. (2025). Women's health funding commitment.

Blank Foundation. Women in philanthropy.

Nature. (2025). Women's health investment trends.

We Will Cure. 5 smart investments for the future of women's health.

Forbes. (2025). Women's health: A trillion-dollar investment frontier.

PubMed. Recent women's health research.

Morgan Stanley. Gender health gap: Technology startups in women's health.

Health Policy Watch. (2025). Gates Foundation to invest $2.5 billion in women's health.

[Félix Thiollier – Lady and Her Horse on a Snowy Day, 1899]

The Importance of Investing in Women's Health